Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 19497559)

1.

Predictors of attrition and weight loss success: Results from a randomized controlled trial.

Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Heymsfield SB, Nguyen AM.

Behav Res Ther. 2009 Aug;47(8):685-91. doi: 10.1016/j.brat.2009.05.004. Epub 2009 May 20.

2.

Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.

Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.

Int J Obes (Lond). 2005 Feb;29(2):208-16.

PMID:
15583700
3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

Randomized trial of lifestyle modification and pharmacotherapy for obesity.

Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ.

N Engl J Med. 2005 Nov 17;353(20):2111-20.

5.

Impact of weight loss on the metabolic syndrome.

Phelan S, Wadden TA, Berkowitz RI, Sarwer DB, Womble LG, Cato RK, Rothman R.

Int J Obes (Lond). 2007 Sep;31(9):1442-8. Epub 2007 Mar 13.

PMID:
17356528
6.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
7.

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.

Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C.

Arch Intern Med. 2001 Jan 22;161(2):218-27.

PMID:
11176735
8.

Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial.

Digenio AG, Mancuso JP, Gerber RA, Dvorak RV.

Ann Intern Med. 2009 Feb 17;150(4):255-62.

PMID:
19221377
9.

Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.

Smith IG, Goulder MA; Sibutramine Clinical Study 1047 Team.

J Fam Pract. 2001 Jun;50(6):505-12.

PMID:
11407998
10.

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.

Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rössner S, Saris W, Van Gaal L, James W, Goulder M; STORM Study Group.

Int J Obes Relat Metab Disord. 2001 Apr;25(4):496-501.

PMID:
11319653
11.

Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine.

Budd GM, Hayman LL, Crump E, Pollydore C, Hawley KD, Cronquist JL, Berkowitz RI.

J Cardiovasc Nurs. 2007 Jul-Aug;22(4):288-96.

PMID:
17589281
12.

Changes in symptoms of depression with weight loss: results of a randomized trial.

Faulconbridge LF, Wadden TA, Berkowitz RI, Sarwer DB, Womble LG, Hesson LA, Stunkard AJ, Fabricatore AN.

Obesity (Silver Spring). 2009 May;17(5):1009-16. doi: 10.1038/oby.2008.647. Epub 2009 Feb 5.

13.

Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.

Elfhag K, Finer N, Rössner S.

Diabetes Obes Metab. 2008 Jun;10(6):498-505. Epub 2007 Jun 26.

PMID:
17593239
14.

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.

Kaukua JK, Pekkarinen TA, Rissanen AM.

Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.

PMID:
14770192
15.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
16.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
17.

Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity.

Farina MG, Baratta R, Nigro A, Vinciguerra F, Puglisi C, Schembri R, Virgilio C, Vigneri R, Frittitta L.

Obes Surg. 2012 Apr;22(4):565-71. doi: 10.1007/s11695-011-0514-y.

PMID:
21901285
18.

Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.

Finer N, Ryan DH, Renz CL, Hewkin AC.

Diabetes Obes Metab. 2006 Mar;8(2):206-13.

PMID:
16448525
19.

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.

Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.

Int J Obes (Lond). 2008 Apr;32(4):692-9. Epub 2007 Dec 11.

PMID:
18071341
20.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.

Am J Psychiatry. 2005 May;162(5):954-62.

PMID:
15863798
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk